Use of the investigational non-opioid analgesic resiniferatoxin appeared to improve pain control in patients with advanced cancer who had intractable pain, though all patients experienced adverse ...

Acute pain is reported in nearly 60% of pediatric emergency department (ED) visits, Olejnik and colleagues noted, and "clinical management of acute pain remains variable," with opioids often given ...

Medically reviewed by Lindsay Cook, PharmD Bladder control problems, or urinary incontinence, can cause an uncontrolled ...

A Novel Non-Opioid Multimodal Analgesic from Xgene Pharmaceutical Reduces Pain and a Need for Opioid Consumption in a Post-Surgical Pain Trial ...

The US Food and Drug Administration has approved the use of a novel painkiller for short-term moderate-to-severe pain in adults. It’s the first of a new class of analgesics to be approved in ...

Taiwanese pharmaceutical company Xgene Pharmaceutical announced that its non-opioid analgesic drug XG005 has reduced acute pain in patients after surgery in a Phase IIb study [MV1] .

Analgesics Market Analgesics Market Dublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Analgesics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The ...

This laboratory model could be used to help explain certain pain syndromes, and offer a new way to test potential analgesic drugs, a Stanford team reports in the journal Nature.

Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice ...

Chronic pain affects more than 50 million Americans and remains one of the most difficult conditions to treat safely and effectively. While opioids have long been a cornerstone of pain management, ...

Use of the investigational non-opioid analgesic resiniferatoxin appeared to improve pain control in patients with advanced cancer who had intractable pain, though all patients experienced adverse ...